September 2018 doi:10.5837/bjc.2018.s11
British Heart Foundation The biggest independent funder of cardiovascular research in the UK, The British Heart Foundation plays a leading role in the fight against diseases of the heart and circulation by support of vital, pioneering research into their causes, prevention, diagnosis and treatment through research grants. It funds around £100 million of heart research every year. https://www.bhf.org.uk/research/information-for-researchers British Cardiovascular Society/BJCA The British Cardiovascular Society is a registered charity that aims to support and represents those working in cardiovascular care and research, by providing access to t
September 2018 doi:10.5837/bjc.2018.s11
A summary of an article written by Dr Aaron Koshy and Professor Andrew L Clark
‘The NHS has indicated that research is a clear priority in improving healthcare for patients’ Figure 1. The case trial timeline, intervals are in days A summary of the article’s key learning points Obtaining approval for conducting clinical research can be an extremely lengthy endeavor (see figure below). The process makes a four-month term in research almost useless, unless you begin the application process at least nine months in advance of a trial’s expected start date. You will need more than a year if you are applying for external funding. Work closely with the relevant organisations, particularly the R&D department of
September 2018 doi:10.5837/bjc.2018.s11
BJC Staff
Importance of UK collaboration with the EU The partnerships between the UK and other EU Member States significantly increase the impact and influence of the EU’s science and research activity. When collaborating with the UK, the share of EU co-authored publications in the top 10% of highly cited publications in medical and health research is higher.2 The UK is also a top five collaboration partner for each of the other 27 Member States,3 and contributed almost 20% of the total research work carried out within EU health programmes between 2007–2016.2 European collaboration is particularly important in some fields – stratified medicine a
September 2018 doi:10.5837/bjc.2018.s11
This article is based on a presentation made by Dr Mark Toms and Dr Tom Thuren
This investment in research also benefits the UK economy providing employment, trade, and addressing shortfalls in STEM skills (Science, Technology, Engineering, and Mathematics). In addition to giving patients faster access to treatments, getting efficacious and safe medicines registered more efficiently enables the trial sponsor to gain reimbursement for those medications sooner. Evolving bio-pharmaceutical model Medical research changed dramatically with the discovery of the structure of DNA and the subsequent understanding of genetic code, with DNA sequencing and amplification. This has led to medicines becoming increasingly personalised
September 2018 doi:10.5837/bjc.2018.s11
This article is based on a presentation made by Professor John Pepper
The Institute of Cardiovascular Medicine and Science (ICMS) is a world-class body set up to improve outcomes in cardiovascular medicine drawing on the combined clinical expertise of its founding partners: Royal Brompton and Hare eld NHS Foundation Trust (RB&HFT) and Liverpool Heart and Chest Hospital NHS Foundation Trust (LHCH). Founded in 2011 as a joint venture, it was formed as a company limited by guarantee and registered at Companies’ House. Initial investment by each Trust of £50,000 was followed up by further investment in 2015 of £50,000 by each Trust. It is supported by its academic partner, Imperial College London. The I
September 2018 doi:10.5837/bjc.2018.s11
This article is based on a presentation made by Professor Martin Gibson
The innovative and trustworthy use of routinely collected healthcare data has enabled a UK company, NorthWest Ehealth, experts in the use of this technology, to become the only organisation in the world to have evaluated the safety and effectiveness of a pre-license medicine in a real-world setting. Its technology can support the whole clinical trial lifecycle and enable more effective feasibility, economic modelling, recruitment, real-time safety monitoring and data analytics. ‘The use of electronic healthcare records for clinical research is helping change the clinical trial landscape’ The EHR and future of clinical trials The use of e
September 2018 doi:10.5837/bjc.2018.s11
‘The UK is a dynamic place to conduct research’ This handbook seeks to introduce the research landscape in the UK. There are many different avenues that research can take. These include research in academic institutions, healthcare organisations, charities and industry. There is much collaboration and partnership between different sectors, including sharing of big data. This environment, with its excellent academic, clinical and commercial interaction, makes the UK a dynamic place to conduct research. We describe some UK research models in this handbook based, in part, on presentations made at a meeting, sponsored by Novartis, entitled �
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits